Medication info

Akigajeong 50/500 mg

Prescription medicationTablet
Ingredient · strength
Niraparib Tosylate Monohydrate›79.7mg / 1 tabletAbiraterone Acetate Micronized›500mg / 1 tablet
Manufacturer / importer
Janssen Korea Ltd.
Appearance
Oval film-coated tablets ranging from orange-yellow to brownish-yellow.
Packaging
56 tablets/box [28 tablets/PTP x 2]
Approval status
Active

MFDS item code 202302816 · Approved 2023.09.25

Summary

Main use
Treatment of BRCA-mutated metastatic castration-resistant prostate cancer in patients who have not received chemotherapy
Who uses it
Adults
Adult dosage
The recommended dose of this medicine is niraparib 200mg / abiraterone acetate 1000mg (two 100mg/500mg tablets), administered once daily at approximately the same time each day. This medicine must be administered on an empty stomach. It must be administered at least 2 hours after a meal, and no food should be consumed for at least 1 hour after administration. Swallow the tablets whole with water; do not chew, break, or crush them (see Precautions for Use, 14. Information for Healthcare Professionals, 1) Pharmacokinetic Information, (1) Absorption). This medicine is administered in combination with prednisolone 10mg daily. When this medicine is administered in combination with prednisolone to patients with BRCA gene mutation-positive metastatic castration-resistant prostate cancer, confirm that the BRCA gene mutation is positive. For the diagnostic method used in the clinical trial, see Precautions for Use, Section 5. General Precautions. If a dose of this medicine or prednisolone is missed, take it as soon as possible on the same day and resume the regular schedule the following day. Do not take an additional dose to make up for the missed dose. Treatment should be continued until disease progression or unacceptable toxicity occurs. For patients who experience a Grade 3 or higher nonhematologic adverse reaction, temporarily interrupt treatment and initiate appropriate medical management (see Precautions for Use). Do not resume treatment with this medicine until the toxic symptoms have resolved to Grade 1 or baseline. For patients who experience Grade 3 or higher or intolerable hematologic toxicity, consider temporarily interrupting treatment and providing supportive care rather than permanently discontinuing this medicine. If hematologic toxicity does not recover to an acceptable level within 28 days of treatment interruption, permanently discontinue this medicine. Grade 1 No change; consider weekly monitoring. Grade 2 Monitor at least weekly and consider withholding this medicine until recovery to Grade 1 or baseline. 1 Weekly monitoring is recommended for 28 days after restarting this medicine. Grade 3 or higher Consider withholding this medicine until platelet and neutrophil counts recover to Grade 1 or baseline1 (monitor at least weekly). Then resume treatment with this medicine or, if necessary, administer 2 lower-dose tablets (50mg/500mg). Weekly blood cell count monitoring is recommended for 28 days after resuming treatment. Second occurrence of Grade 3 or higher Withhold this medicine and monitor at least weekly until platelet and/or neutrophil counts recover to Grade 1. When treatment is resumed, start with 2 lower-dose tablets (50mg/500mg). Weekly monitoring is recommended for 28 days after resuming treatment with this medicine. If the patient was already receiving the lower-dose tablets of this medicine (50mg/500mg), consider discontinuing treatment. Third occurrence of Grade 3 or higher Permanently discontinue this medicine. 1 During temporary interruption of treatment with this medicine, healthcare professionals may consider and administer abiraterone acetate with prednisone or prednisolone to maintain the daily dose of abiraterone acetate (see the prescribing information for abiraterone acetate). Treatment with this medicine may be resumed only when toxicity due to thrombocytopenia and neutropenia improves to Grade 1 or recovers to baseline. If necessary, treatment may be resumed at the lower dose of this medicine, 50mg/500mg (2 tablets). For the most common adverse reactions, see Precautions for Use, Section 4. Adverse Reactions. For Grade 3 or higher anemia, temporarily interrupt this medicine and manage with supportive care until recovery to Grade 2 or lower. If anemia persists, consider dose reduction (2 tablets of 50mg/500mg) based on clinical judgment. Grade 1 No change; consider weekly monitoring. Grade 2 If baseline anemia is Grade 1 or lower, monitor at least weekly for 28 days. Grade 3 or higher Withhold this medicine and1 provide supportive care, with monitoring at least weekly until recovery to Grade 2 or lower. If anemia persists, consider dose reduction (2 tablets of 50mg/500mg) based on clinical judgment. Second occurrence of Grade 3 or higher Withhold this medicine and provide supportive care, with monitoring at least weekly until recovery to Grade 2 or lower. When treatment is resumed, start with 2 lower-dose tablets (50mg/500mg tablets). Weekly monitoring is recommended for 28 days after resuming treatment with this medicine. If the patient was already receiving the lower-dose tablets of this medicine (50mg/500mg), consider discontinuing treatment. Third occurrence of Grade 3 or higher Consider discontinuing treatment with this medicine based on clinical judgment. 1 During temporary interruption of treatment with this medicine, healthcare professionals may consider and administer abiraterone acetate with prednisone or prednisolone to maintain the daily dose of abiraterone acetate (see the prescribing information for abiraterone acetate). A complete blood count should be obtained before starting treatment and monitored weekly during the first month, every 2 weeks for the next 2 months, monthly for the remainder of the first year, and every 2 months thereafter for clinically significant changes in hematologic parameters during treatment (see Precautions for Use). Serum aminotransferases and total bilirubin should be measured before starting treatment, every 2 weeks during the first 3 months of treatment, monthly for the remainder of the first year, and every 2 months thereafter during treatment. Serum potassium should be monitored monthly during the first year of treatment and every 2 months thereafter during treatment (see Precautions for Use). Blood pressure should be monitored weekly for the first 2 months, monthly for the first year, and every 2 months thereafter during treatment. This medicine should not be administered to patients with moderate to severe hepatic impairment (see 14. Information for Healthcare Professionals – 1) Pharmacokinetic Information – (5) Special Populations). For patients who develop Grade 3 or higher hepatotoxicity (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] increased to 5 times or more the upper limit of normal [ULN]) or total bilirubin exceeding 3 times the ULN, temporarily interrupt treatment with this medicine and closely monitor liver function (see Precautions for Use). If a patient develops severe hepatotoxicity (ALT or AST at 20 times the ULN) while receiving this medicine, treatment should be permanently discontinued. Permanently discontinue this medicine in patients with ALT exceeding 3 times the ULN and total bilirubin exceeding 2 times the ULN in the absence of biliary obstruction or other causes of concurrent elevations (see Precautions for Use). No dose adjustment is necessary for patients with mild to moderate renal impairment. Use of this medicine is not recommended in patients with severe renal impairment, as it has not been studied in this population (see 14. Information for Healthcare Professionals – 1) Pharmacokinetic Information – (5) Special Populations).

Ingredients

Importer
Janssen Korea Ltd.

Efficacy & effects

Treatment of BRCA-mutated metastatic castration-resistant prostate cancer in patients who have not received chemotherapy

View approved original text

This medication is used in patients with metastatic castration-resistant prostate cancer who have BRCA gene mutations and is administered in conjunction with prednisone for adult patients who have not received chemotherapy. This treatment helps suppress the growth of cancer cells and slows the progression of prostate cancer. It provides customized treatment based on the patient’s condition and contributes to improving the overall effectiveness of cancer treatment. Therefore, it is effectively used for BRCA mutation metastatic castration-resistant prostate cancer.

Dosage and Administration

Adult dosage

The recommended dose of this medicine is niraparib 200mg / abiraterone acetate 1000mg (two 100mg/500mg tablets), administered once daily at approximately the same time each day. This medicine must be administered on an empty stomach. It must be administered at least 2 hours after a meal, and no food should be consumed for at least 1 hour after administration. Swallow the tablets whole with water; do not chew, break, or crush them (see Precautions for Use, 14. Information for Healthcare Professionals, 1) Pharmacokinetic Information, (1) Absorption). This medicine is administered in combination with prednisolone 10mg daily. When this medicine is administered in combination with prednisolone to patients with BRCA gene mutation-positive metastatic castration-resistant prostate cancer, confirm that the BRCA gene mutation is positive. For the diagnostic method used in the clinical trial, see Precautions for Use, Section 5. General Precautions. If a dose of this medicine or prednisolone is missed, take it as soon as possible on the same day and resume the regular schedule the following day. Do not take an additional dose to make up for the missed dose. Treatment should be continued until disease progression or unacceptable toxicity occurs. For patients who experience a Grade 3 or higher nonhematologic adverse reaction, temporarily interrupt treatment and initiate appropriate medical management (see Precautions for Use). Do not resume treatment with this medicine until the toxic symptoms have resolved to Grade 1 or baseline. For patients who experience Grade 3 or higher or intolerable hematologic toxicity, consider temporarily interrupting treatment and providing supportive care rather than permanently discontinuing this medicine. If hematologic toxicity does not recover to an acceptable level within 28 days of treatment interruption, permanently discontinue this medicine. Grade 1 No change; consider weekly monitoring. Grade 2 Monitor at least weekly and consider withholding this medicine until recovery to Grade 1 or baseline. 1 Weekly monitoring is recommended for 28 days after restarting this medicine. Grade 3 or higher Consider withholding this medicine until platelet and neutrophil counts recover to Grade 1 or baseline1 (monitor at least weekly). Then resume treatment with this medicine or, if necessary, administer 2 lower-dose tablets (50mg/500mg). Weekly blood cell count monitoring is recommended for 28 days after resuming treatment. Second occurrence of Grade 3 or higher Withhold this medicine and monitor at least weekly until platelet and/or neutrophil counts recover to Grade 1. When treatment is resumed, start with 2 lower-dose tablets (50mg/500mg). Weekly monitoring is recommended for 28 days after resuming treatment with this medicine. If the patient was already receiving the lower-dose tablets of this medicine (50mg/500mg), consider discontinuing treatment. Third occurrence of Grade 3 or higher Permanently discontinue this medicine. 1 During temporary interruption of treatment with this medicine, healthcare professionals may consider and administer abiraterone acetate with prednisone or prednisolone to maintain the daily dose of abiraterone acetate (see the prescribing information for abiraterone acetate). Treatment with this medicine may be resumed only when toxicity due to thrombocytopenia and neutropenia improves to Grade 1 or recovers to baseline. If necessary, treatment may be resumed at the lower dose of this medicine, 50mg/500mg (2 tablets). For the most common adverse reactions, see Precautions for Use, Section 4. Adverse Reactions. For Grade 3 or higher anemia, temporarily interrupt this medicine and manage with supportive care until recovery to Grade 2 or lower. If anemia persists, consider dose reduction (2 tablets of 50mg/500mg) based on clinical judgment. Grade 1 No change; consider weekly monitoring. Grade 2 If baseline anemia is Grade 1 or lower, monitor at least weekly for 28 days. Grade 3 or higher Withhold this medicine and1 provide supportive care, with monitoring at least weekly until recovery to Grade 2 or lower. If anemia persists, consider dose reduction (2 tablets of 50mg/500mg) based on clinical judgment. Second occurrence of Grade 3 or higher Withhold this medicine and provide supportive care, with monitoring at least weekly until recovery to Grade 2 or lower. When treatment is resumed, start with 2 lower-dose tablets (50mg/500mg tablets). Weekly monitoring is recommended for 28 days after resuming treatment with this medicine. If the patient was already receiving the lower-dose tablets of this medicine (50mg/500mg), consider discontinuing treatment. Third occurrence of Grade 3 or higher Consider discontinuing treatment with this medicine based on clinical judgment. 1 During temporary interruption of treatment with this medicine, healthcare professionals may consider and administer abiraterone acetate with prednisone or prednisolone to maintain the daily dose of abiraterone acetate (see the prescribing information for abiraterone acetate). A complete blood count should be obtained before starting treatment and monitored weekly during the first month, every 2 weeks for the next 2 months, monthly for the remainder of the first year, and every 2 months thereafter for clinically significant changes in hematologic parameters during treatment (see Precautions for Use). Serum aminotransferases and total bilirubin should be measured before starting treatment, every 2 weeks during the first 3 months of treatment, monthly for the remainder of the first year, and every 2 months thereafter during treatment. Serum potassium should be monitored monthly during the first year of treatment and every 2 months thereafter during treatment (see Precautions for Use). Blood pressure should be monitored weekly for the first 2 months, monthly for the first year, and every 2 months thereafter during treatment. This medicine should not be administered to patients with moderate to severe hepatic impairment (see 14. Information for Healthcare Professionals – 1) Pharmacokinetic Information – (5) Special Populations). For patients who develop Grade 3 or higher hepatotoxicity (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] increased to 5 times or more the upper limit of normal [ULN]) or total bilirubin exceeding 3 times the ULN, temporarily interrupt treatment with this medicine and closely monitor liver function (see Precautions for Use). If a patient develops severe hepatotoxicity (ALT or AST at 20 times the ULN) while receiving this medicine, treatment should be permanently discontinued. Permanently discontinue this medicine in patients with ALT exceeding 3 times the ULN and total bilirubin exceeding 2 times the ULN in the absence of biliary obstruction or other causes of concurrent elevations (see Precautions for Use). No dose adjustment is necessary for patients with mild to moderate renal impairment. Use of this medicine is not recommended in patients with severe renal impairment, as it has not been studied in this population (see 14. Information for Healthcare Professionals – 1) Pharmacokinetic Information – (5) Special Populations).

Precautions

This medication may cause severe hematological malignancies such as myelodysplastic syndrome or acute myeloid leukemia, so additional evaluation by a specialist is necessary if there are symptoms suggestive of blood cancer or if hematological toxicity persists for an extended period. It should not be used in individuals allergic to this medication's ingredients or excipients, in pregnant or breastfeeding women, or in patients with moderate to severe liver impairment. Patients with hereditary metabolism disorders such as galactose intolerance or lactose enzyme deficiency should also not take this medication. The use of radium-223 dichloride in conjunction is not recommended, as this combination may increase the risk of fractures and mortality and requires caution. Patients with hypertension, hypokalemia, fluid retention, or cardiovascular disease should be carefully administered this medication, as it can increase mineralocorticoid levels, worsening these symptoms. Caution is also required for patients with severe renal impairment when using this medication. Common side effects associated with this medication include anemia, constipation, hypertension, nausea, fatigue, thrombocytopenia, weakness, pain, loss of appetite, vomiting, neutropenia, arthralgia, urinary tract infections, insomnia, headaches, dyspnea, abdominal pain, peripheral edema, hypokalemia, dizziness, nasopharyngitis, bronchitis, conjunctivitis, leukopenia, hypertriglyceridemia, depression, anxiety, confusion, palpitations, atrial fibrillation, tachycardia, heart failure, myocardial infarction, pneumonitis, and dyspepsia. Hematological adverse reactions, such as anemia, thrombocytopenia, and neutropenia, mainly occur early in treatment and may require regular blood tests for monitoring and dosage adjustments or treatment discontinuation if necessary. Blood pressure should be adequately controlled before administration and monitored regularly during treatment. Patients with a history of heart disease should carefully manage cardiac function and monitor for symptoms, considering drug discontinuation if severe cardiac abnormalities arise. Since there is a risk of liver function abnormalities or hepatotoxicity, frequent liver function tests should be conducted before and during treatment, and treatment should be suspended if liver levels rise significantly. There may be an increased risk of infection, so careful observation for symptoms of infection is essential, and symptoms of pulmonary embolism should also be promptly evaluated and treated. Rarely, this medication may cause a reversible posterior leukoencephalopathy syndrome that can affect brain function; if symptoms such as seizures, headache, or visual disturbances occur, immediate consultation with healthcare professionals is necessary. Diabetic patients should closely monitor blood glucose changes, and monitoring for adrenal function impairment is essential upon discontinuation of corticosteroids. Women who are pregnant or may become pregnant should take care to avoid exposure to this medication and should use effective contraception during the treatment period and for four months after the last dose. The safety and efficacy of this medication in children have not been established, and for elderly patients, special dose adjustments are not required. There is no specific antidote for overdose, so symptomatic treatment will be provided according to symptoms. This medication may require caution when operating vehicles or machinery, so one should act carefully during such activities. Keep this medication out of the reach of children and store it in the original container to prevent misuse or degradation of quality.

Side effects

Anemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature to preserve its effectiveness over time.

Appearance and packaging

Appearance

Oval film-coated tablets ranging from orange-yellow to brownish-yellow.

Package unit

56 tablets/box [28 tablets/PTP x 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.